Global Leaders in Biologics
RTI Biologics Announces Launch of BioAdapt™ DBM Foam
- Robert Jordheim
- Chief Financial Officer
- Wendy Crites Wacker
- Corporate Communications
ALACHUA, Fla. (June 30, 2011) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, announces the launch of BioAdapt™ DBM Foam, a flexible demineralized bone matrix (DBM) solution with unique handling capabilities. The first implantation occurred June 24, 2011 in a foot and ankle procedure.
BioAdapt is the newest addition to RTI’s broad osteobiologic product portfolio. Designed to maximize ease of use, BioAdapt is a sterile, room temperature implant offered in five pre-shaped options to meet the bone grafting needs of trauma, reconstructive, spine and extremity surgeons. With foam-like properties, BioAdapt expands with hydration to adapt to the contours of the surgical site. This versatile implant offers flexible, yet cohesive handling characteristics, making it easy to shape or mold to fit various defects.
BioAdapt will be available exclusively from RTI Biologics. To learn more about BioAdapt please visit www.rtix.com or contact RTI’s customer service department at 1-800-624-7238.
About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.
RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Three such processes – the BioCleanse® Tissue Sterilization Process, the Cancelle™ SP DBM Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.
RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.
Forward Looking Statement
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.